Axovant Sciences announced that David Hung, MD, has been named Chief Executive Officer of the company, effective April 7, 2017. Dr. Hung, who also joined the company's Board of Directors, succeeds founding Chief Executive Officer Vivek Ramaswamy. Ramaswamy will continue to serve on the company's Board of Directors and will lead parent company and majority owner Roivant Sciences as its full-time Chief Executive Officer.

Hung brings more than 20 years of leadership and management experience in the life sciences industry. He was the founder, President, and Chief Executive Officer of Medivation through its acquisition by Pfizer for approximately $14 billion in September 2016.